BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹350.70
- Market cap
- ₹57,153 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 115.4×Sector 46.1×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Legal & Regulatory
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
- Value
- ₹3.21 Cr
Biocon Employee Stock Options
Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr